EVH Evolent Health, Inc.
Services-Management Services · NYSE · SEC CIK 1628908 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.1%
TTM net income YoY-296.1%
TTM EPS YoY-187.3%
Revenue 3-yr CAGR9.4%
Net income 3-yr CAGR—
Margins
Gross margin15.0%
Operating margin-18.5%
Net margin-21.7%
FCF margin—
EBITDA margin-13.9%
Returns
ROE-83.6%
ROA-23.0%
ROIC (approx.)-23.0%
Asset turnover1.06x
Leverage & solvency
Liabilities / assets81.0%
Debt / equity2.60x
Current ratio1.26x
Interest coverage-6.23x
Cash quality & payout
Operating cash flow / net income-0.13x
Accruals ratio-25.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.88B | $2.55B | $1.96B | $1.35B | $907.96M |
| Cost of revenue | $1.48B | $2.19B | $1.50B | $1.04B | $657.55M |
| Gross profit | $399.88M | $367.35M | $460.47M | $316.58M | $250.41M |
| R&D expense | — | — | — | — | $15.50M |
| SG&A expense | $303.87M | $263.05M | $358.11M | $269.27M | $219.50M |
| Operating income | -$410.14M | -$40.48M | -$71.21M | $3.64M | -$42.41M |
| Interest expense | $57.47M | $24.72M | $54.20M | $15.57M | $25.43M |
| Pretax income | -$534.64M | -$63.04M | -$202.41M | -$62.08M | -$29.80M |
| Income tax | -$126,000 | -$1.41M | -$89.36M | -$43.38M | $483,000 |
| Net income | -$534.51M | -$61.62M | -$113.04M | -$19.16M | -$37.60M |
| EBITDA | -$294.29M | $77.89M | $52.20M | $70.84M | $17.63M |
| EPS (basic) | -5.07 | -0.81 | -1.28 | -0.20 | -0.44 |
| EPS (diluted) | -5.07 | -0.81 | -1.28 | -0.20 | -0.44 |
| Weighted avg. shares (diluted) | 114.21M | 114.68M | 111.25M | 93.70M | 86.07M |
| Balance sheet | |||||
| Cash & equivalents | $151.86M | $178.50M | $223.46M | $215.16M | $354.94M |
| Receivables | $309.86M | $414.68M | $446.75M | $254.68M | $130.60M |
| Current assets | $506.37M | $607.12M | $683.67M | $478.05M | $523.96M |
| PP&E, net | $80.78M | $73.15M | $78.19M | $87.87M | $81.36M |
| Goodwill | $694.48M | $1.14B | $1.12B | $722.77M | $426.30M |
| Intangibles | $584.94M | $680.16M | $752.01M | $442.78M | $279.78M |
| Total assets | $1.90B | $2.54B | $2.68B | $1.82B | $1.42B |
| Current liabilities | $385.26M | $715.50M | $674.24M | $433.44M | $445.49M |
| Short-term debt | $0 | $171.47M | $0 | $0 | $0 |
| Long-term debt | $970.54M | $490.52M | $597.05M | $412.99M | $215.68M |
| Total debt | $970.54M | $661.99M | $597.05M | $412.99M | $215.68M |
| Total liabilities | $1.48B | $1.35B | $1.43B | $957.88M | $725.83M |
| Shareholders' equity | $415.19M | $1.00B | $1.07B | $859.42M | $693.63M |
| Net debt | $818.68M | $483.49M | $373.59M | $197.83M | -$139.27M |
| Cash flow statement | |||||
| Operating cash flow | $38.84M | $18.77M | $142.58M | -$11.55M | $38.75M |
| Investing cash flow | -$233,000 | -$62.93M | -$415.54M | -$259.12M | -$15.79M |
| Financing cash flow | -$35.92M | -$565,000 | $281.34M | $131.54M | -$29.55M |
| Depreciation & amortization | $115.85M | $118.37M | $123.42M | $67.19M | $60.04M |
| Stock-based compensation | $39.74M | $39.75M | $40.50M | $33.98M | $16.71M |
| Share buybacks | $40.00M | $0 | $0 | — | — |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.